Statera Biopharma, Inc. Common Stock
STAB
STAB was delisted on the 11th of January, 2023.
21 hedge funds and large institutions have $2.15M invested in Statera Biopharma, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 0 increasing their positions, 3 reducing their positions, and 3 closing their positions.
225% more capital invested
Capital invested by funds: $661K → $2.15M (+$1.49M)
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
11% more funds holding
Funds holding: 19 → 21 (+2)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$911K |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$48.4K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$31.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$117K |
| 2 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
-$33K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$7.36K |
| 4 |
Morgan Stanley
New York
|
-$419 |
| 5 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
-$197 |
STAB Hedge Fund Activity: Q4 2020 in Review
21 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Statera Biopharma, Inc. Common Stock (STAB) for Q4 2020, worth a combined $2.15M — up 225% from $661K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new STAB positions and 3 closed out — a net gain of 2 holders — while 0 added to existing stakes and 3 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $911K. The largest seller was Renaissance Technologies, cutting an estimated $117K.
- 21 institutional investors held Statera Biopharma, Inc. Common Stock (STAB) as of Q4 2020, up from 19 in Q3 2020.
- Funds reported $2.15M of Statera Biopharma, Inc. Common Stock stock for Q4 2020, up 225% quarter-over-quarter.
- 5 funds opened new Statera Biopharma, Inc. Common Stock positions in Q4 2020 and 3 closed out, a net change of +2 holders.
- The largest Statera Biopharma, Inc. Common Stock buyer in Q4 2020 was Armistice Capital, an estimated $911K added.
- The largest Statera Biopharma, Inc. Common Stock seller in Q4 2020 was Renaissance Technologies, an estimated $117K sold.
Based on aggregated 13F filings for Q4 2020.